Abstract Number: PB2119
Meeting: ISTH 2020 Congress
Background: Venous thromboembolism (VTE) is an independent predictor of poorer survival in cancer patients, however, its impact on mortality of lymphoma patients undergoing autologous hematopoietic stem cell transplantation (ASCT) remains unclear.
Aims: To analyse the incidence of VTE and the impact on survival of patients undergoing ASCT for relapsed/refractory lymphoma.
Methods: 166 adult patients (average age 40 years, range 18-67, 56% men) undergoing ASCT due to relapsed (n=134) or refractory (n=32) non-Hodgkin´s lymphoma (NHL, n=93) or Hodgkin´s lymphoma (HL, n=73) in 2012-2018 were analysed.
Results: 39 events of VTE (23%) were recorded during the follow-up period (median 38, range 2-87 months), including 6 cases during ASCT (3.6%). 32 patients (19.3%) died because of relapse, cardiovascular disease, infectious complications and other cancers. Although 7 of these patients had history of VTE, none of the deaths were VTE-related. More deaths were found among men (23/32, p=0.04). No differences in mortality were found between analysed lymphoma groups (HL vs. NHL, p=0.041). Of 32 patients who relapsed after ASCT, 16 died (p< 0.005). Kaplan-Meier analysis showed no difference in survival between patients with and without history of VTE. In the Cox proportional hazard model only relapse after ASCT (HR 5.19; 95% CI 2.44-11.05, p< 0.0005), age over 50 years (HR 3.04; 95% CI 1.37-6.76, p=0.0063) and male gender (HR 2.57; 95% CI 1.12-5.87, p=0.025) were significantly associated with mortality, Figure 1 shows Kaplan-Meier analyses. Other factors, including HL diagnosis (HR 1.16; 95% CI 0.49-2.76, p=0.74), relapse before ASCT (HR 1.31; 95% CI 0, 63-2.73, p=0.50), after >3 lines of treatment before ASCT (HR 1.29; 95% CI 0.58-2.90, p=0.53) and history of VTE (HR 0.67; 95% CI 0.28-1.62, p=0.38) had no impact on mortality.
Conclusions: Our analysis showed no negative impact of VTE both before and during ASCT on the survival of patients undergoing ASCT due to refractory lymphoma.
To cite this abstract in AMA style:Rupa-Matysek J, Joks M, Matuszak M, Łojko-Dankowska A, Gil L. No Impact of Previous Venous Thromboembolism on the Survival of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Refractory Lymphoma [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/no-impact-of-previous-venous-thromboembolism-on-the-survival-of-patients-undergoing-autologous-hematopoietic-stem-cell-transplantation-for-refractory-lymphoma/. Accessed December 5, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/no-impact-of-previous-venous-thromboembolism-on-the-survival-of-patients-undergoing-autologous-hematopoietic-stem-cell-transplantation-for-refractory-lymphoma/